Patents by Inventor Kevin X. Chen

Kevin X. Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SERIES OF PIPERIDINE-SUBSTITUTED BENZOIC ACID COMPOUNDS, AND USE THEREOF
    Publication number: 20240109861
    Abstract: A series of piperidine-substituted benzoic acid compounds and the use thereof, and specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 30, 2021
    Publication date: April 4, 2024
    Inventors: Kevin X CHEN, Li ZHANG, Houze GUI, Haoyu ZHANG, Huiyu ZHANG, Guoping HU, Jian LI, Shuhui CHEN
  • PYRIDONE MULTIPLE-MEMBERED RING DERIVATIVES AND USE THEREOF
    Publication number: 20240025921
    Abstract: Provided are a class of pyridone multiple-membered ring derivatives and the use thereof. Specifically provided are a compound as represented by formula (VI) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 7, 2022
    Publication date: January 25, 2024
    Inventors: Kevin X CHEN, Jian XIONG, Jingjing WANG, Guoping HU, Jinxin LIU, Yu HAN, Jian LI, Shuhui CHEN
  • TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF
    Publication number: 20230365558
    Abstract: A series of tetrahydroisoquinoline derivatives and the crystal forms thereof. Specifically disclosed are a compound as represented by formula (VII), a crystal form thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2021
    Publication date: November 16, 2023
    Inventors: Kevin X CHEN, Zuhao GUO, Yanxin YU, Boyu HU, Jingjing WANG, Zhaoguo CHEN, Cheng XIE, Jian XIONG, Yongbo FANG, Yingtao LIU, Jian LI, Shuhui CHEN
  • OCTAHYDROPYRAZINODIAZANAPHTHYRIDINE DIONE COMPOUNDS
    Publication number: 20230357272
    Abstract: Disclosed is a class of octahydropyrazinodiazanaphthyridine dione compounds, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 6, 2021
    Publication date: November 9, 2023
    Inventors: Shuhui CHEN, Kevin X CHEN, Kai ZHOU, Wen JIANG, Guoping HU, Jian LI
  • ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES
    Publication number: 20230339943
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 19, 2023
    Publication date: October 26, 2023
    Inventors: Jian XIONG, Chaofeng LONG, Jingjing WANG, Xiaoxin CHEN, KEVIN X. CHEN, Cheng XIE, Peng LI, Xuanjia PENG, Jian Li, Shuhui Chen
  • Anti-influenza virus pyrimidine derivative
    Patent number: 11725009
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: August 15, 2023
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)
    Patent number: 11649239
    Abstract: Disclosed in the present invention are a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound and a preparation method thereof. Further disclosed is a use of the crystal form in the preparation of a medicament for treating A2A receptor related diseases.
    Type: Grant
    Filed: April 28, 2019
    Date of Patent: May 16, 2023
    Assignee: Medshine Discovery Inc.
    Inventors: Kevin X. Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie
  • Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
    Patent number: 11639355
    Abstract: Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: May 2, 2023
    Assignees: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD., SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD., MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Xiaobing Yan, Jianglei Huang, Yuekun Nie, Guoping Hu, Jian Li, Shuhui Chen, Jiaqiang Dong, Tie-Lin Wang
  • PYRIMIDOPYRROLE SPIRO COMPOUNDS AND DERIVATIVES THEREOF AS DNA-PK INHIBITORS
    Publication number: 20230055321
    Abstract: Provided are a class of DNA-PK inhibitor, and specifically, a compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of DNA-PK inhibitor-related drugs.
    Type: Application
    Filed: November 20, 2020
    Publication date: February 23, 2023
    Inventors: Kevin X CHEN, Shanghua XIA, Zhaoguo CHEN, Zuhao GUO, Yanxin YU, Kai ZHOU, Boyu HU, Li ZHANG, Fen JIANG, Jingjing WANG, Guoping HU, Jian LI, Shuhui CHEN
  • PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-PK INHIBITORS
    Publication number: 20230026616
    Abstract: A class of DNA-PK inhibitors, in particular a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug relating to a DNA-PK inhibitor.
    Type: Application
    Filed: November 25, 2020
    Publication date: January 26, 2023
    Inventors: Kevin X CHEN, Shanghua XIA, Zhaoguo CHEN, Zuhao GUO, Yanxin YU, Kai ZHOU, Boyu HU, Li ZHANG, Fen JIANG, Jingjing WANG, Guoping HU, Jian LI, Shuhui CHEN
  • Crystal form and salt form of pyridoimidazole compound and preparation method therefor
    Patent number: 11535613
    Abstract: Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: December 27, 2022
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Xiaoxin Chen, Jingjing Wang, Zhuowei Liu, Kevin X Chen, Chengwu Liu, Cheng Xie, Chaofeng Long, Peng Li, Jian Li, Shuhui Chen
  • Borate of azetidine derivative
    Patent number: 11466036
    Abstract: A borate compound of an azetidine derivative, relating in particular to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof or a geometric isomer thereof, as well as a use thereof in the preparation of a drug used for the treatment or prevention of multiple myeloma.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: October 11, 2022
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Jian Xiong, Cheng Xie, Xiongbin Xu, Kevin X Chen, Jian Li, Shuhui Chen, Aiming Zhang, Xiquan Zhang, Xin Tian
  • Bicylic compound acting as an inhibitor
    Patent number: 11466024
    Abstract: A bicyclic compound acting as a ROR? inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR? inhibitory activities, being expected to be used for treating diseases mediated by ROR? receptors in a mammal.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: October 11, 2022
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Medshine Discovery Inc.
    Inventors: Kevin X Chen, Kai Zhou, Yanxin Yu, Boyu Hu, Linghui Wu, Xiaoyuan Chen, Jiangfeng Lin, Haomin Chen, Xiangjian Wang, Xiquan Zhang, Xin Tian, Hongjiang Xu
  • SALT AND CRYSTAL FORM OF MTORC1/2 DUAL KINASE ACTIVITY INHIBITOR AND PREPARATION METHOD THEREFOR
    Publication number: 20220306622
    Abstract: Disclosed are a salt and a crystal form of an mTORC1/2 dual kinase inhibitor and a preparation method therefor. Also disclosed is use of the salt and crystal form in the preparation of a medicament related to the mTORC1/2 dual kinase inhibitor.
    Type: Application
    Filed: May 6, 2020
    Publication date: September 29, 2022
    Inventors: Kevin X CHEN, Zhaoguo CHEN, Li ZHANG, Yanxin YU, Kai ZHOU, Fen JIANG, Shanghua XIA, Xiaofei WANG
  • MACROCYCLIC DERIVATIVES AS FACTOR XIA INHIBITORS
    Publication number: 20220281868
    Abstract: Macrocyclic derivatives, preparation methods therefor and pharmaceutical compositions comprising said derivatives, and uses thereof as therapeutic agents, especially as factor XIa inhibitors and in drugs for treating and preventing thromboembolisms and other diseases. Specifically disclosed is a compound represented by formula (I), and an isomer and pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 23, 2020
    Publication date: September 8, 2022
    Inventors: Yaxian CAI, Xiaobing YAN, Zhe CAI, Guoping HU, Charles Z. DING, Kevin X CHEN, Jian LI, Shuhui CHEN
  • QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA-PK INHIBITOR
    Publication number: 20220267310
    Abstract: Disclosed in the present invention are a compound as represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof, and disclosed is an application thereof in preparing drugs for treating DNA-PK inhibitor-related diseases.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 25, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Zhaoguo Chen, Li Zhang, Boyu Hu, Shuhui Chen
  • CRYSTAL FORM AND SALT OF QUINAZOLINE COMPOUND AND PREPARATION METHOD THEREOF
    Publication number: 20220242851
    Abstract: The present invention relates to a crystal form and a salt of a compound serving as a Pan-HER tyrosine kinase inhibitor and a preparation method therefor, and also use thereof in the preparation of a medicament for treating solid tumors.
    Type: Application
    Filed: June 19, 2020
    Publication date: August 4, 2022
    Applicants: SHENZHEN JINRUI FOUNDATION BIOTECH CO., LTD, MEDSHINE DISCOVERY INC.
    Inventors: Kevin X. CHEN, Li ZHANG, Kai ZHOU, Yanxin YU, Boyu HU, Huiyu ZHANG
  • Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors
    Patent number: 11377444
    Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 5, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Zhaoguo Chen, Li Zhang, Yanxin Yu, Kai Zhou, Boyu Hu, Xiaofei Wang, Guoping Hu, Jian Li, Shuhui Chen
  • SALT FORM AND CRYSTAL FORM OF A2A RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR
    Publication number: 20220185825
    Abstract: Provided are a salt form and a crystal form of adenosine A2A receptor antagonist, and preparation method therefor. Also provided is an application of the salt form or crystal form in the preparation of a medicine for A2A receptor-related diseases, the maleate salt in the salt form has a structure of formula (I).
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Inventors: Kevin X CHEN, Kai ZHOU, Yanxin YU, Boyu HU, Li ZHANG, Zhaoguo CHEN
  • ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE
    Publication number: 20220135558
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 24, 2021
    Publication date: May 5, 2022
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen